Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease

Recent studies have shown that type 2 diabetes is preventable by both lifestyle interventions and medications that influence primary glucose metabolism. Whether pharmacological interventions that influence primary lipid metabolism can also delay development of type 2 diabetes is unknown. The goal of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Circulation (New York, N.Y.) N.Y.), 2004-05, Vol.109 (18), p.2197-2202
Hauptverfasser:	TENENBAUM, Alexander, MOTRO, Michael, FISMAN, Enrique Z, SCHWAMMENTHAL, Ehud, ADLER, Yehuda, GOLDENBERG, Ilan, LEOR, Jonathan, BOYKO, Valentina, MANDELZWEIG, Lori, BEHAR, Solomon
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Bezafibrate - pharmacology Bezafibrate - therapeutic use Biological and medical sciences Blood and lymphatic vessels Blood Glucose - analysis Cardiology. Vascular system Cholesterol - blood Comorbidity Coronary Disease - blood Coronary Disease - complications Diabetes Mellitus, Type 2 - epidemiology Diabetes Mellitus, Type 2 - prevention & control Disease Progression Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous Female Follow-Up Studies Glucose Intolerance - blood Glucose Intolerance - complications Glucose Intolerance - drug therapy Humans Hypercholesterolemia - blood Hypercholesterolemia - complications Hypercholesterolemia - drug therapy Hypolipidemic Agents - pharmacology Hypolipidemic Agents - therapeutic use Incidence Insulin - blood Life Tables Male Medical sciences Middle Aged Myocardial Infarction - complications Receptors, Cytoplasmic and Nuclear - agonists Transcription Factors - agonists
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!